EUVIMEDEUVIMED entdecken
Vergleichsstudie

Comparison of Three Treatment Strategies in Mild Asthma: A Carbon-Utility Analysis

Rafael José Vieira, Vítor Henrique Duarte, Antonio Bognanni, Sara Gil-Mata, Manuel Marques-Cruz, Ana Margarida Pereira, José Chen-Xu, Renaud Louis, Sian Williams, Kari C Nadeau, Tari Haahtela, Thomas Piggott und 5 weitere

The Journal of Allergy and Clinical Immunology: In Practice · 2025

DOI: 10.1016/j.jaip.2025.06.035 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2025. Verfasst von Rafael José Vieira und 16 weiteren Autor:innen. Beteiligte Einrichtung: MEDCIDS-Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, Porto, Portugal; CINTES…. Hauptthemen laut MEDLINE: Asthma, Budesonide, Albuterol, Anti-Asthmatic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: Horizon Europe.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The main types of commercially available inhalers for the management of asthma include dry powder inhalers (DPIs) and pressurized metered-dose inhalers (pMDIs). The environmental impact of pMDIs, due to hydrofluorocarbon propellants, is a growing concern. OBJECTIVE: To conduct a carbon-utility analysis in mild asthma, comparing the clinical efficacy of DPIs versus pMDIs alongside their associated environmental impacts. METHODS: We performed a carbon-utility analysis using data from the Novel START trial, comparing 3 treatment strategies for mild asthma: as-needed budesonide/formoterol DPI, as-needed salbutamol pMDI, and maintenance budesonide DPI plus as-needed salbutamol pMDI. We calculated carbon dioxide equivalent (kgCO2e) emissions per quality-adjusted life year (QALY) gained. Results were compared to predefined willingness-to-emit thresholds based on health care CO2e emissions in the United States, the European Union, and the United Kingdom. RESULTS: As-needed budesonide/formoterol DPI had a yearly carbon footprint of 1.1 kgCO2e and a utility of 0.936, compared with 26.2 kgCO2e and 0.935 for as-needed salbutamol pMDI, and 17.3 kgCO2e and 0.944 for maintenance budesonide DPI plus as-needed salbutamol pMDI. Compared with budesonide/formoterol, budesonide plus salbutamol resulted in 2192 more kgCO2e per QALY gained, exceeding the US per capita kgCO2e emissions in the health care sector and its 2030 target values. As-needed salbutamol was associated with higher CO2e emissions and lower utilities than budesonide/formoterol. CONCLUSION: We applied to the asthma field a novel methodological approach to consider both the environmental impact and effectiveness of interventions. These findings indicate that as-needed budesonide/formoterol DPI is the preferred option when considering both carbon emissions and treatment effectiveness.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaBudesonideAlbuterolAnti-Asthmatic AgentsBronchodilator AgentsHumansDry Powder InhalersMetered Dose InhalersFemaleMaleAdultCarbon DioxideQuality-Adjusted Life YearsMiddle AgedFormoterol FumarateCarbon FootprintAdministration, Inhalation

Stichwörter der Autor:innen

AsthmaCarbon footprintHydrofluorocarbonsInhalersPlanetary healthQuality-adjusted life years

Substanzen

BudesonideAlbuterolAnti-Asthmatic AgentsCarbon DioxideBronchodilator AgentsFormoterol Fumarate

Autor:innen und Institutionen

  • MEDCIDS-Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, Porto, Portugal; CINTESIS@RISE-Health Research Network, Faculty of Medicine, University of Po…
  • Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada; Clinical Epidemiology and Research Center (CERC), IRCCS Humanitas Research Hospital, Humanitas University, Milan, It…
  • NOVA National School of Public Health, Public Health Research Centre, NOVA University Lisbon, Lisbon, Portugal; ISGlobal, Barcelona Institute for Global Health, Barcelona, Spain.
  • Department of Pneumology, CHU Liège, Liège, Belgium; GiGAI3 Research Group, University of Liège, Liège, Belgium.
  • International Primary Care Respiratory Group IPCRG, Edinburgh, United Kingdom.
  • Harvard T.H. Chan School of Public Health, Harvard University, Cambridge, Mass.

Förderung

  • Horizon Europe

Zitieren

APA

Vieira, R. J., Duarte, V. H., Bognanni, A., Gil-Mata, S., Marques-Cruz, M., Pereira, A. M., Chen-Xu, J., Louis, R., Williams, S., Nadeau, K. C., Haahtela, T., Piggott, T., Fonseca, J. A., Antó, J. M., Schünemann, H. J., Bousquet, J., & Sousa-Pinto, B. (2025). Comparison of Three Treatment Strategies in Mild Asthma: A Carbon-Utility Analysis. The Journal of Allergy and Clinical Immunology: In Practice. https://doi.org/10.1016/j.jaip.2025.06.035

Vancouver

Vieira RJ, Duarte VH, Bognanni A, Gil-Mata S, Marques-Cruz M, Pereira AM, et al. Comparison of Three Treatment Strategies in Mild Asthma: A Carbon-Utility Analysis. The Journal of Allergy and Clinical Immunology: In Practice. 2025. doi:10.1016/j.jaip.2025.06.035

BibTeX
@article{Vieira2025,
  author = {Vieira, Rafael José and Duarte, Vítor Henrique and Bognanni, Antonio and Gil-Mata, Sara and Marques-Cruz, Manuel and Pereira, Ana Margarida and Chen-Xu, José and Louis, Renaud and Williams, Sian and Nadeau, Kari C and Haahtela, Tari and Piggott, Thomas and Fonseca, João A and Antó, Josep M and Schünemann, Holger J and Bousquet, Jean and Sousa-Pinto, Bernardo},
  title = {Comparison of Three Treatment Strategies in Mild Asthma: A Carbon-Utility Analysis},
  journal = {The Journal of Allergy and Clinical Immunology: In Practice},
  year = {2025},
  doi = {10.1016/j.jaip.2025.06.035}
}
Kostenlos starten →